At 10:23 am; Nifty Pharma index, the largest loser among sectoral indices, was down 1.5% as compared to a marginal 0.02% decline in the Nifty 50 index. In past three trading sessions, the pharma index slipped 3.3% as against 1% fall in the benchmark index.
Among the individual stocks, Biocon has slipped 8% to Rs 347 after the US Food and Drug Administration (FDA) issued Form 483 with 10 observations after inspecting the company’s Bengaluru plant. CLICK HERE FOR REPORT.
Biocon on Monday, On July 31, 2017, said that this USFDA visit was a part of the regular periodic audit for small molecule injectable.
The company has responded to the regulator with a corrective and preventive action plan and is on track to implement them in timely manner, the company spokesperson said in response to media queries regarding the USFDA visit to Biocon in the month of May/June 2017.
Lupin and Dr Reddy’s Laboratories hits their respective fresh 52-week lows after they reported a weak set of numbers in April-June (Q1FY17) quarter. Sun Pharmaceutical Industries, too, hit 52-week low of Rs 493 on NSE in intra-day trade.
Lupin has lowered its FY18 Ebitda (Earnings before interest, taxation, depreciation and amortization) margin guidance by 500bps owing to higher-than-expected erosion in Glumetza and price pressures in the US base business.
Analysts at IIFL Institutional Equities expect Lupin’s US revenue to decline 20% cc in FY18 due to Glumetza/Fortamet sales erosion. Most of the key near-term launches are expected to begin only in 2HFY18.
COMPANY | LATEST | PREV CLOSE | LOSS(%) |
BIOCON | 352.90 | 375.30 | -6.0 |
CADILA HEALTH. | 526.40 | 546.10 | -3.6 |
SUN PHARMA.INDS. | 502.20 | 516.20 | -2.7 |
DR REDDY'S LABS | 2270.40 | 2331.85 | -2.6 |
NATCO PHARMA | 943.00 | 965.20 | -2.3 |
MARKSANS PHARMA | 40.55 | 41.45 | -2.2 |
AUROBINDO PHARMA | 725.55 | 741.35 | -2.1 |
LUPIN | 976.45 | 994.90 | -1.9 |
TORRENT PHARMA. | 1229.45 | 1252.05 | -1.8 |
GLENMARK PHARMA. | 690.70 | 702.25 | -1.6 |
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in